ХРОНИЧЕСКИЙ ЛИМФОЛЕЙКОЗ И ИОНИЗИРУЮЩАЯ РАДИАЦИЯ
Ключові слова:
хронический лимфолейкоз, радиогенность, ЧернобыльАнотація
В отличие от других форм лейкоза, хронический лимфолейкоз (ХЛЛ) до последнего времени не относили к числу радиогенных. Однако подобная концепция может быть пересмотрена в свете данных последних исследований. В обзоре проанализированы данные эпидемиологических исследований
работников атомной промышленности, а также больных, подвергавшихся
воздействию ионизирующего излучения, которые свидетельствуют о возможной радиогенной природе возникновения ХЛЛ. При этом учитываются как изменения, внесенные в классификацию, так и новые представления о патогенезе этого заболевания. Рассмотрены также результаты исследований ХЛЛ среди больных из числа ликвидаторов последствий аварии
на Чернобыльской атомной электростанции.
Посилання
Finch SC, Linet MS. Chronic leukaemias. Bail Clin Haematol 1992; 5: 27–56.
Groves FD, Linet MS, Devesa SS. Patterns of occurrence of the leukaemias. Eur J Cancer 1995; 31A: 941–9.
Jaffe ES, Harris NL, Stein H, Vardiman YW (eds). Pathology and genetics of haematopoietic and lymphoid tissues. Lyon:
IARC Press, 2001. 351 p.
Swerdlow Sh, Campo E, Harris NL, et al. (eds). WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press, 2008. 439p.
Magrath J. Molecular basis of lymphomagenesis. Cancer Res 1992; 52: 5529–40.
Stilgenbauer S, Bullinger L, Lichter P, Dohner H. Genetic features of B-cell chronic lymphocytic leukemia: genomic aberrations and V(H) gene mutation status in pathologenesis and clinical course. Leukemia 2002; 16: 993–1007.
Chiorazzi N, Rai KR, Ferrarini M. Chronic lymphocytic leukemia. N Engl Med 2005; 352: 804–15.
Dighiero G, Hamblin TJ. Chronic lymphocytic leukaemia. Lancet 2008; 371: 1017–29.
Linet MS, Schubauer-Berigan MK, Weissenburger DD, et al. Chronic lymphocytic leukaemia: an overview of aetiology in light of recent developments in classification and pathogenesis. Br J Haematol 2007; 139: 672–86.
Vrijheid M, Cardis E, Blettner M, et al. The 15-country collaborative study of cancer risk among radiation workers in the nuclear industry: design, epidemiological methods and descriptive results. Radiat Res 2007; 167: 361–79.
Calin GA, Liu CG, Sevignani C, et al. MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias. Proc Natl acad Sci USA 2004; 101: 11755–60.
Nicoloso MS, Kipps TJ, Croce CM, Calin GA. MicroRNAs in the pathogeny of chronic lymphocytic leukaemia. Br J Haematol 2007; 139: 709–16.
Caporaso N, Goldin L, Plass C, et al. Chronic lymphocytic leukaemia genetics overview. Br J Haematol 2007; 139: 630–4.
Döhner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000; 343: 1910–6.
Morrell D, Cromartie E, Swift M. Mortality and cancer incidence in 263 patients with ataxia teleangiectasia. J Natl Cancer Inst 1986; 77: 89–92.
Khanna KK. Cancer risk and the ATM gene: a continuing debate. J Natl Cancer Inst 2000; 92: 795–802.
Taylor AM, Metcalfe JA, Thick J, Mak YF. Leukemia and lymphoma in ataxia teleangiectasia. Blood 1996; 87: 423–38.
Richardson DB, Wing S, Schroeder J, et al. Ionizing radiation and chronic lymphocytic leukemia. Environ Health Perspect 2005; 113: 1–5.
Schaffner C, Stilgenbauer S, Rappold GA, et al. Somatic ATM mutations indicate a pathogenic role of ATM in B-cell chronic lymphocytic leukemia. Blood 1999; 94: 748–53.
Stankovic T, Weber P, Stewart G, et al. Inactivation of ataxia teleangiectasia mutated gene in B-cell chronic lymphocytic leukaemia. Lancet 1999; 353: 26–9.
Boultwood J, Wainscoat JS. Gene silencing by DNA methylation in haematological malignancies. Br J Haematol 2007; 138: 3–11.
Plass C, Byrd JC, Raval A, et al. Molecular profiling of chronic lymphocytic leukaemia: genetics meets epigenetics to identify predisposing genes. Br J Haematol 2007; 139: 744–52.
Hamblin TJ. How we been wrong about ionizing radiation and chronic lymphocytic leukemia? Leuk Res 2008; 12: 523–5.
Finch SC, Hoshito T, Itoga T, et al. Chronic lymphocytic leukemia in Hiroshima and Nagasaki, Japan. Blood 1969; 33: 79–86.
Bizzozero OJ Jr, Johnson KG, Ciocco A, et al. Radiationrelated leukemia in Hiroshima and Nagasaki 1946–1964 II. Ann
Inter Med 1967; 66: 522–30.
Ishimaru T, Hoshino T, Ishimaru M, et al. Leukemia in atomic bomb survivors: Hiroshima and Nagasaki. TR-25–69. Hiroshima, Japan: Atomic Bomb Casualty Commission: 1969.
Rai KR, Sawitsky A, Gronkite ER, et al. Chronic staging of chronic lymphocytic leukemia. Blood 1975; 46; 219–34.
Catrwright RA, McNally RJQ, Rowland DJ, Thomas J. The descriptive epidemiology of leukemia and related conditions in parts of the United Kingdom 1984–1993. Leukaemia Research Found. London, 1997.
Hsu WL, Preston DL, Soda M, et al. The incidence of leukemia, lymphoma and multiple myeloma among atomic bomb survivors: 1950–2001. Radiat Res 2013; 179: 361–82.
Court-Brown W, Doll R. Mortality from cancer and other causes after radiotherapy for ankylosing spondylitis. Br Med J 1965; 2: 1327–32.
Darby SC, Doll R, Gill SK, Smith PG. Long term mortality after a single treatment course with X-rays in patients for ankylosing spondylitis. Br J Cancer 1987; 55: 179–90.
Preston DL, Kusumi S, Tomonaga M, et al. Cancer incidence in atomic bomb survivors. Part III. Leukemia, lymphoma and multiple myeloma, 1950–1987. Radiat Res 1994; 137: S68–S97.
Weiss HA, Darby SC, Fearn T, Doll R. Leukemia mortality after X-rays treatment for ankylosing spondylitis. Radiat Res 1995; 142: 1–11.
Damber L, Larsson LG, Johansson L, Norin T. A cohort study with regard to the risk of haematological malignancies in patients treated with X-rays for benign lesions in the locomotor system. I. Epidemiological analysis. Acta Oncol 1995; 34: 713–9.
Inskip PD, Kleinerman RA, Stovall M, et al. Leukemia, lymphoma and multiple myeloma after pelvic radiotherapy for benign disease. Radiat Res 1993; 135: 108–24.
Boice JD Jr, Day NE, Andersen A, et al. Second cancer following radiation treatment for cervical cancer. An international collaboration among cancer registries. J Natl Cancer Inst 1985; 74: 955–75.
Curtis RE, Boice JD Jr, Stovall M, et al. Leukemia risk following radiotherapy for breast cancer. J Clin Oncol 1989; 7: 21–9.
Curtis RE, Boice JD Jr, Stovall M, et al. Relation of leukemia risk to radiation dose following cancer of the uterine corpus. J Natl Cancer Inst 1994; 86: 1315–24.
Cardis E, Gilbert I, Howe G, et al. Combined analyses of cancer mortality among nuclear industry workers in Canada, the United Kingdom and the United States of America. IARC Technical Report No. 25 Lyon, 1995.
Davis FG, Boice JD Jr, Hrubec Z, et al. Cancer mortality in the radiation-exposed cohort of Massachusetts tuberculosis
patients. Cancer Res 1989; 49: 6130–6.
Schubauer-Berigan MK, Daniels RD, Fleming DA, et al. Chronic lymphocytic leukaemia and radiation: findings among workers at five US nuclear facilities and a review of the recent literature. Br J Haematol 2007; 139: 799–808.
Stevens W, Thomas DC, Lyon JL, et al. Leukemia in Utah and radioactive fallout from the Nevada test site. A case-control study. JAMA 1990; 264: 585–91.
Thaul S, Page WF, Crawford H, O’Maonaigh H. The five series study: mortality of military participants in US nuclear weapons tests. National Academy Press, Washington, DC.
Muirhead CR, Bingham D, Haylock RG, et al. Follow up of mortality and incidence of cancer 1952–98 in men from the UK who participated in UK’s atmospheric nuclear weapon tests and experimental programmes. Occup Environ Med 2003; 60 (3): 165–72.
Shilnikova NS, Preston DL, Ron E, et al. Cancer mortality risk among workers at the Mayak nuclear complex. Radiat Res 2003; 159: 787–98.
Krestinina LY, Preston DL, Ostroumova EV, et al. Protracted radiation exposure and cancer mortality in the Techa river cohort. Radiat Res 2005; 164: 602–11.
Vrijheid M, Cardis E, Ashmore P, et al. Ionizing radiation and risk chronic lymphocytic leukemia in the 15-country study of nuclear industry workers. Radiat Res 2008; 170: 661–5.
Silver ShR, Hiratzka Sh, Schubauer-Berigan MK, Daniels RD. Chronic lymphocytic leukemia radiogenicity: a systematic review Cancer Causes Control 2007; 18: 1077–93.
Smith PG, Doll R. Mortality from cancer and all causes among British radiologists. Br J Radiol 1981; 54 (639): 187–94.
Doody MM, Mandel JS, Lubin JH, Boice JD Jr. Mortality among United States radiologic technologists, 1926–90. Cancer Causes Control 1998; 9 (1): 67–75.
Darby SC, Whitley E, Howe GR, et al. Radon and cancer other than lung cancer in underground miners: a collaborative analysis of 11 studies. J Natl Cancer Inst 1995; 87 (5): 378–84.
Rericha V, Kulich M, Rericha R, et al. Incidence of leukemia and multiple myeloma in Czech uranium miners: a case-cohort study. Environ Health Perspect 2006; 114 (6): 818–22.
Schwartz GG, Klug MG. Incidence rates of chronic lymphocytic leukemia in US states are associated with residential radon levels. Future Oncol 2016; 12 (2): 165–74.
Alexander FE, McKinney PA, Cartwright RA. Radon and leukemia. Lancet 1990; 335: 1336–7.
Hague A, Kirk A. Environmental radon and cancer risk. Radiat Prot Dosim 1992; 45 (1–4): 639–42.
Gluzman DF, Abramenko IV, Machilo VM. Large granular lymphocyte leukemia in clean-up workers. Exp Oncol 2000; 22 (1–2): 84–5.
Осечинский ИВ, Иванов ЕП, Мартиросов АР и др. Эпидемиология гемобластозов в регионе вокруг Чернобыля. I. Организация исследования в Гомельской области. Гематол трансфузиол 1991; 5: 36–8.
Klymenko V, Kryachok I, Dyagil I, et al. Some clinical and hematological features of CLL in persons who suffered from the Chernobyl incident in Ukraine in 1980. In: XIII Int Wokrshop on CLL. Paris, 1999. 43.
Kryachok I, Polyshchuk O, Dyagil I, et al. Comparative analysis of CLL in persons who suffered after Chernobyl accident and in unexposed CLL patients. Haematologica 2005; 90: 454A.
Abramenko IV, Bilous NI, Chumak AA, et al. Lymphocytic leukemia in patients exposed to ionizing radiation due to the Chernobyl NPP accident — with focus on immunoglobulin heavy chain gene analysis. Leuk Res 2008; 32: 535–45.
Savli H, Gluzman DF, Sunnetci D, Zavelevich MP. Quantitative real time PCR analysis of apoptosis-related gene expression in leukemias in Ukrainian patients. Exp Oncol 2011; 33 (2): 104–6.
Savli H, Sunnetci D, Cine N, Gluzman DF, et al. Gene expression profiling of B-CLL in Ukrainian patients in post-Chernobyl period. Exp Oncol 2012; 34 (1): 57–63.
Savli H, Akkoynlu RU, Cine N, Gluzman DF. Deregulated levels of the NF-kB1, NF-kB2 and Rel genes in Ukrainian patients with leukemia and lymphoma in the post-Chernobyl period. Turk J Haematol 2015 doi: 10.4274/trk.2014.0190.
Ivanov VK, Tsyb AF, Gorsky AI, et al.Elevated leukemia rates in Chernobyl accident liquidators. BMJ, Rapid Responses, April 15, 2003.
Kesminiene A, Evrard AS, Ivanov VK, et al. Risk of hematological malignancies among Chernobyl liquidators. Radiat Res 2008, 170: 721–35.
Romanenko AY, Finch SC, Hatch M, et al. The Ukrainian-American study of leukemia and related disorders among Chernobyl cleanup workers from Ukraine: III. Radiation risks. Radiat Res 2008; 170: 711–20.
Zablotska LB, Bazyka D, Lubin JH, et al. Radiation and the risk of chronic lymphocytic and other leukemias among Cnernobyl cleanup workers. Environ Health Perspect 2013; 121: 59–65.
Finch SC, Dyagil I, Reiss RF, et al. Clinical characteristics of chronic lymphocytic leukemia occurring in Chernobyl cleanup workers. Hematol Oncol 2016; DOI 10.1002/hon.2278.
